Abstract
Nearly all cases of Ewing Family Tumors (EFT) harbor chimeric EWS/ETS transcription factors which are thought to aberrantly regulate transcriptional targets of phenotypic consequence. We have recently demonstrated that EWS/ETS proteins up-regulate platelet derived growth factor-C (PDGF-C), a novel transforming growth factor. To determine if PDGF-C signaling contributes to the malignant phenotype of EFT cell lines, we attempted to disrupt this presumed autocrine loop. AG1296, a PDGF receptor selective tyrosine kinase inhibitor, markedly inhibits anchorage-independent growth in an EFT cell line. To effect specific disruption, we have developed a dominant negative form of PDGF-C which is appropriately secreted and processed. This mutant has greatly reduced activity as a PDGF receptor agonist. When co-expressed with PDGF-C in a fibroblast transformation model, this dominant negative dramatically inhibits anchorage-independent growth. When this mutant is expressed in EFT cell lines, there is a similar reduction in anchorage-independent growth. This demonstrates that specific inhibition of PDGF-C signaling in EFT cell lines partially reverts their phenotype. These data support a significant role of PDGF-C in the biology of EFT. They also suggest that PDGF-C driven signaling may be a possible therapeutic target of more clinically relevant tyrosine kinase inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaronson SA . 1991 Science 254: 1146–1153
Antoniades HN, Galanopoulos T, Neville-Golden J, O'Hara CJ . 1992 Proc. Natl. Acad. Sci. USA 89: 3942–3946
Bejcek BE, Li DY, Deuel TF . 1989 Science 245: 1496–1499
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB . 2000 J. Pharmacol. Exp. Ther. 295: 139–145
Cowley S, Paterson H, Kemp P, Marshall CJ . 1994 Cell 77: 841–852
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G . 1992 Nature 359: 162–165
Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins KC, Aaronson SA, Antoniades HN . 1983 Science 221: 275–277
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . 2001 N. Engl. J. Med. 344: 1031–1037
Duan DS, Pazin MJ, Fretto LJ, Williams LT . 1991 J. Biol. Chem. 266: 413–418
Ekman S, Thuresson ER, Heldin CH, Ronnstrand L . 1999 Oncogene 18: 2481–2488
Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE . 2001 J. Biol. Chem. 276: 27406–27414
Guha A, Dashner K, Black PM, Wagner JA, Stiles DA . 1995 Int. J. Cancer 60: 168–173
Hanahan D, Weinberg RA . 2000 Cell 100: 57–70
Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M . 1992 Cancer Res. 52: 3213–3219
Horowitz ME, Malawer MM, Woo SY, Hicks MJ . 1997 Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors Philadelphia: Lippincott-Raven
Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A . 1994 Cancer Res. 54: 6106–6114
Krystal GW, Carlson P, Litz J . 1997 Cancer Res. 57: 2203–2208
Kumar R, Mandal M, Vadlamudi R . 2000 Semin. Oncol. 27: 84–91 discussion 92–100
Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U . 2000 Nat. Cell. Biol. 2: 302–309
Look AT . 1995 Adv. Cancer Res. 67: 25–57
May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT . 1993a Proc. Natl. Acad. Sci. USA 90: 5752–5756
May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT . 1993b Mol. Cell. Biol. 13: 7393–7398
Mercola M, Deininger PL, Shamah SM, Porter J, Wang CY, Stiles CD . 1990 Genes Dev. 4: 2333–2341
Nakayama Y, Sueishi K, Oka K, Kono S, Tomonaga M . 1998 Surg. Neurol. 49: 181–187 discussion 187–188
Nanberg E, Westermark B . 1993 J. Biol. Chem. 268: 18187–18194
Ostman A, Heldin CH . 2001 Adv. Cancer Res. 80: 1–38
Rabbitts TH . 1994 Nature 372: 143–149
Radig K, Schneider-Stock R, Rose I, Mittler U, Oda Y, Roessner A . 1998 Pathol. Res. Pract. 194: 157–162
Rice AB, Moomaw CR, Morgan DL, Bonner JC . 1999 Am. J. Pathol. 155: 213–221
Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio N, Horenstein AL, Pistamiglio P, Vai S, Berger M, di Montezemolo LC, Madon E, Basso G . 1998 Blood 91: 2397–2405
Schaeffer HJ, Weber MJ . 1999 Mol. Cell. Biol. 19: 2435–2444
Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N . 1998 Cancer Res. 58: 4127–4131
Shamah SM, Stiles CD, Guha A . 1993 Mol. Cell. Biol. 13: 7203–7212
Silvany RE, Eliazer S, Wolff NC, Ilaria Jr RL . 2000 Oncogene 19: 4523–4530
Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH . 2001 Cancer Res. 61: 5778–5783
Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A . 2000 Mod. Pathol. 13: 632–637
Sundberg C, Branting M, Gerdin B, Rubin K . 1997 Am. J. Pathol. 151: 479–492
Uutela M, Lauren J, Bergsten E, Li X, Horelli-Kuitunen N, Eriksson U, Alitalo K . 2001 Circulation 103: 2242–2247
Vassbotn FS, Langeland N, Hagen I, Holmsen H . 1990 Biochim. Biophys. Acta 1054: 246–249
Vignaud JM, Marie B, Klein N, Plenat F, Pech M, Borrelly J, Martinet N, Duprez A, Martinet Y . 1994 Cancer Res. 54: 5455–5463
Zwerner JP, May WA . 2001 Oncogene 20: 626–633
Acknowledgements
WA May is supported with funding from the American Cancer Society (RPG-99-096-01) and the National Cancer Institute (CA90666). The authors wish to acknowledge Dr Randy Wada for critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zwerner, J., May, W. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 21, 3847–3854 (2002). https://doi.org/10.1038/sj.onc.1205486
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205486
Keywords
This article is cited by
-
The Tumor Microenvironment of Pediatric Sarcoma: Mesenchymal Mechanisms Regulating Cell Migration and Metastasis
Current Oncology Reports (2019)
-
Platelet-derived growth factor-C functions as a growth factor in mouse embryonic stem cells and human fibrosarcoma cells
Cellular & Molecular Biology Letters (2018)
-
Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature
Journal of Neuro-Oncology (2016)
-
The Potential for molecular therapeutic targets in Ewing’s sarcoma
Current Treatment Options in Oncology (2005)
-
VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis
The EMBO Journal (2004)